Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -108.41% is 1778% below its 3-year average of -5.77%, near the low end of its 3-year range (-121.37%–47.56%).
58.04% below its 12-month average of -68.60%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 15.42%.
EBITDA MARGIN
-108.41%
EBITDA MARGIN AVG TTM
-68.60%
EBITDA MARGIN AVG 3Y
-5.77%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-58.04%
CURRENT VS 3Y AVG
-1778.20%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Baird Medical Investment Holdings Limited
Market Cap
$31.36M
EBITDA Margin
-108.41%
TTM Avg
-68.60%
3Y Avg
-5.77%
5Y Avg
N/A
Market Cap
$30.65M
EBITDA Margin
-10097.04%
TTM Avg
-6618.17%
3Y Avg
-8743.58%
5Y Avg
-8072.84%
Market Cap
$32.31M
EBITDA Margin
-29.82%
TTM Avg
-228.84%
3Y Avg
-176.67%
5Y Avg
-120.12%
Market Cap
$32.32M
EBITDA Margin
-2671.72%
TTM Avg
-3785.12%
3Y Avg
-14400.08%
5Y Avg
-14400.08%
Market Cap
$33.42M
EBITDA Margin
-3982.39%
TTM Avg
-3087.93%
3Y Avg
-1849.71%
5Y Avg
-2051.20%
Market Cap
$33.52M
EBITDA Margin
-7905.63%
TTM Avg
-7905.63%
3Y Avg
-7905.63%
5Y Avg
-7905.63%
Market Cap
$28.43M
EBITDA Margin
-40038.95%
TTM Avg
-34141.60%
3Y Avg
-20873.74%
5Y Avg
-16727.01%
Market Cap
$27.31M
EBITDA Margin
-17954.61%
TTM Avg
-17954.61%
3Y Avg
-17954.61%
5Y Avg
-17954.61%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Baird Medical Investment Holdings Limited (BDMD) | $31.36M | -108.41% | -68.60% | -5.77% | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $30.92M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $30.65M | -10097.04% | -6618.17% | -8743.58% | -8072.84% |
| EUDA Health Holdings Limited (EUDA)vs › | $32.31M | -29.82% | -228.84% | -176.67% | -120.12% |
| BeyondSpring Inc. (BYSI)vs › | $32.32M | -2671.72% | -3785.12% | -14400.08% | -14400.08% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.42M | -3982.39% | -3087.93% | -1849.71% | -2051.20% |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.52M | -7905.63% | -7905.63% | -7905.63% | -7905.63% |
| aTyr Pharma, Inc. (ATYR)vs › | $28.43M | -40038.95% | -34141.60% | -20873.74% | -16727.01% |
| GridAI Technologies Corp. (GRDX)vs › | $27.31M | -17954.61% | -17954.61% | -17954.61% | -17954.61% |
| Accuray Incorporated (ARAY)vs › | $35.89M | -6.58% | -1.77% | -0.14% | 1.64% |
Gross Margin
83.8%
EBITDA Margin
-108.4%
Operating Margin
-113.3%
Net Margin
-121.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 15.42% |
| 2025-12-31 | -99.84% |
| 2025-06-30 | -121.37% |
| 2024-12-31 | 45.07% |
| 2024-06-30 | 43.25% |
| 2023-12-31 | 47.56% |
| 2023-06-30 | 29.50% |
